Public methods overview · Version 1.1
Make the evidence-to-action pathway inspectable.
P4L uses this framework to evaluate sources, bound claims, distinguish interpretation, support decisions, connect communications to meaning, and test the conditions for adoption and impact.
Purpose: This overview explains P4L’s method for decision-oriented research and communications. Specialized scientific, clinical, legal, regulatory, or reimbursement review remains specific to the work.
Workflow
Signal → Evidence → Decision → Adoption → Impact
Controls
What public P4L work should show.
Source hierarchy
- Primary or authoritative records for current institutional, program, regulatory, and policy status
- Peer-reviewed human evidence and authoritative guidance for health and clinical claims
- Secondary sources only when their added interpretation is necessary and attributable
Claim classes
- Source fact: directly supported by the cited record
- P4L interpretation: a bounded synthesis or implication
- Hypothesis: a proposition requiring further evidence
- Scenario: a conditional future possibility, not a forecast
Evidence strength
- Established human evidence
- Emerging human evidence with limitations
- Mechanistic or preclinical evidence
- Unknown, conflicting, unsupported, or overstated
Status precision
Proposed, announced, funded, selected, accepted, enrolled, authorized, cleared, launched, operational, completed, effective, and scaled are not interchangeable.
Outcome precision
A biomarker, digital signal, engagement measure, delivery event, functional outcome, clinical outcome, operational result, and economic result must not be treated as equivalents.
Context and safety
Population, setting, intended use, material limitations, uncertainty, access, equity, burden, safety, and relevant regulatory boundaries travel with the claim.
Review and currency
Substantive artifacts identify authorship, dates, sources, limitations, and review or update status appropriate to the work.
Disclosure
Material financial, advisory, employment, sponsor, personal, or institutional relationships that could affect interpretation should be disclosed at the artifact level.
Generative AI
AI may assist ideation, structure, editing, metadata, source discovery, coding, and repetitive checks. It is not the authority for consequential factual, health, policy, regulatory, legal, or biographical claims; a human must verify and approve them.
Method in practice
Source-linked work should remain useful as the landscape changes.
P4L records are designed to evolve with evidence, policy, program status, and implementation learning. Important records carry the sources, dates, status, and limitations needed for current use.
Evidence scope
Public corpus coverage
The current public corpus is a curated launch slice centered on authoritative program, policy, regulatory, standards, and R&D sources. It is not a comprehensive clinical evidence review of prevention, healthspan, longevity, interventions, biomarkers, technologies, outcomes, economics, or markets. Coverage is expanding by defined evidence track, with source type, population, method, uncertainty, applicability, and review status kept visible.
Evidence architecture
Eight evidence tracks
Expansion is organized through these tracks. Publication within a track does not imply comprehensive coverage.
Human outcomes
mortality, morbidity, function, quality of life, cognition, independence, adverse events, and patient experience.
Measures and endpoints
clinical outcome assessments, biomarkers, digital measures, functional tests, composite endpoints, validity, and meaningful change.
Prevention interventions
physical activity, nutrition and Food as Medicine, sleep, tobacco, alcohol, weight, hypertension, diabetes, mental health, vaccination, and screening.
Technologies and care models
diagnostics, wearables, remote monitoring, AI, digital therapeutics, MedTech, home-based care, and proactive-care workflows.
Implementation and adoption
workflow, workforce, procurement, usability, adherence, clinician trust, organizational readiness, scale, and sustainability.
Payment and economics
coverage, payment models, total cost, utilization, budget impact, incentives, and affordability.
Equity and access
population representation, disability, digital and rural access, language, affordability, differential performance, and distribution of benefit or burden.
Science and market landscape
trials, research programs, standards, companies, products, funding, partnerships, and competition, kept separate from evidence of benefit.
Record contract
Clinical and scientific evidence record schema
Every public evidence record carries explicit values or an explicit not-reported/not-applicable state; missing values are not inferred.
- Claim supported
- Source type and design
- Population and setting
- Intervention/exposure and comparator
- Outcome or endpoint
- Follow-up duration
- Effect estimate and uncertainty
- Harms/adverse events
- Missing data and attrition
- Bias/limitations
- Applicability/generalizability
- Funding/conflicts
- Replication or corroboration
- Decision use
- Last reviewed / review due
For this decision
Controlled audiences: Public/patients · Clinicians · Health-system leaders · Payers/employers · Policymakers · Researchers · Innovators · Funders/investors · Media/civil society.